Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome

Guohua Song, Min Li, Hui Sang, Living Zhang, Xiuhong Li, Shutong Yao, and Shucun Qin

Key Laboratory of Atherosclerosis in Universities of Shandong, Shandong, China; Institute of Atherosclerosis, Institute of Nursing, and Institute of Basic Medicine, Taishan Medical University, Shandong, China; and Taishan Mental Diseases Hospital, Shandong, China

Abstract We have found that hydrogen (dihydrogen; H₂) has beneficial lipid-lowering effects in high-fat diet-fed Syrian golden hamsters. The objective of this study was to characterize the effects of H₂-rich water (0.9–1.0 L/day) on the content, composition, and biological activities of serum lipoproteins on 20 patients with potential metabolic syndrome. Serum analysis showed that consumption of H₂-rich water for 10 weeks resulted in decreased serum total-cholesterol (TC) and LDL-cholesterol (LDL-C) levels. Western blot analysis revealed a marked decrease of apolipoprotein (apo)B100 and apoE in serum. In addition, we found H₂ significantly improved HDL functionality assessed in four independent ways, namely, i) protection against LDL oxidation, ii) inhibition of tumor necrosis factor (TNF)-α-induced monocyte adhesion to endothelial cells, iii) stimulation of cholesterol efflux from macrophage foam cells, and iv) protection of endothelial cells from TNF-α-induced apoptosis. Further, we found consumption of H₂-rich water resulted in an increase in antioxidant enzyme superoxide dismutase and a decrease in thiobarbituric acid-reactive substances in whole serum and LDL. In conclusion, supplementation with H₂-rich water seems to decrease serum LDL-C and apoB levels, improve dyslipidemia-injured HDL functions, and reduce oxidative stress, and it may have a beneficial role in prevention of potential metabolic syndrome.—Song, G., M. Li, H. Sang, L. Zhang, X. Li, S. Yao, Y. Yu, C. Zong, Y. Xue, and S. Qin. Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. J. Lipid Res. 2013. 54: 1884–1893.

Supplementary key words apolipoprotein B • antioxidative property • low density lipoprotein • high density lipoprotein

Hydrogen (dihydrogen; H₂), as the lightest and most abundant chemical element, is considered a novel antioxidant that can reduce oxidative stress (1). Hydrogen gas has come to the forefront of therapeutic medical gas research. Accumulated evidence in a variety of biomedical fields using clinical and experimental models for many diseases proves that H₂ administered either through gas inhalation or consumption of an aqueous H₂-containing solution, can act as a feasible therapeutic strategy in different disease models. For example, supplementation with H₂-rich water was demonstrated to have a beneficial role in prevention of types 1 and 2 diabetes and insulin resistance (2, 3); chronic liver inflammation (4); acute oxidative stress; and focal brain ischemia/reperfusion injury (1). In addition, we have reported that consumption of H₂-saturated saline for eight weeks prevent atherosclerosis in apolipoprotein E-knockout (apoE⁻/⁻) mice (5) and that administration of H₂-saturated saline for four weeks decreases serum total cholesterol (TC) and LDL-cholesterol (LDL-C) levels in high-fat diet-fed hamsters (6). However, the lipid-regulating effect of H₂ in humans has not yet been demonstrated. Therefore, the aim of this study was to characterize the effects of H₂ on the content and composition of serum lipoproteins in patients with potential dyslipidemia.

Metabolic syndrome is characterized by a constellation of metabolic and anthropometric abnormalities, which include excess weight, insulin resistance, hyperglycemia, hypertension, low concentration of HDL-cholesterol (HDL-C),...
H₂ decreases LDL-C level and improves HDL function 1885

METHODS

Subjects

The study protocol was approved by the Ethics Committee of Taishan Medical University. We recruited 20 subjects ≥ 43 years of age, males (n = 12) and females (n = 8), from existing patient databases or by advertisement. In this study, subjects were required to have one or more of the following conditions: prehypertension (diastolic blood pressure of 80–89 mmHg and systolic blood pressure of 139 mmHg or lower); prediabetes (fasting serum glucose from 5.2 to 6.9 mmol/l); TC > 5.18 mmol/l and/or LDL-C > 2.59 mmol/l; body mass index (BMI) between 25.0 and 34.9 kg/m²; or waist circumference ≥ 100 cm for males and ≥ 88 cm for females. All participants provided written informed consent to participate before enrollment in the study.

Study design and preparation of H₂ water

The patients consumed 0.9–1.0 l/day of H₂-rich pure water for 10 weeks. A plastic shelled product (Premium FDR, Friendear, Tokyo, Japan) consisting of metallic magnesium (99.9% pure) and natural stones in 500 ml of polypropylene water bottles (NongFu Spring, HangZhou, China) was used to produce H₂. The product was capable of generating H₂ when placed in drinking water by the following chemical reaction: Mg + 2H₂O → Mg (OH)₂ + H₂. The H₂ water stick was placed into the sealed water bottle for 12 h before consumption by the patients. The water was drunk by patients within 15 min after opening the sealed cap, and the H₂ concentration was maintained between 0.2 and 0.25 mM and pH between 7.8 and 8.2 measured by a H₂ sensor (Unisense, Denmark) for continuous 15 min after opening the sealed cap. Subjects were instructed to reuse the magnesium sticks by transferring the sticks to a new bottle of water after use. In summary, subjects were expected to consume 450–500 ml of H₂-rich water two times/day for a total minimum consumption of 900 ml to a maximum consumption of 1,000 ml. The blood samples were collected at baseline (0 week) and after 10 weeks of drinking H₂ water.

Serum analysis

Serum lipids. Blood samples were obtained in the morning after an overnight fast. Serum glucose levels were measured by the glucose oxidase method. Serum TC, HDL-C, LDL-C, and triacylglycerols (TG) were measured by enzymatic methods on a chemical autoanalyzer (Hitachi Co, Tokyo, Japan). Lipoprotein profiles were obtained by fast-protein liquid chromatography (FPLC) using Superose 6 10/300GL column (17). Briefly, 100 μl of fasting serum was applied to a Superose 6 column, and the samples were eluted in a mobile phase (0.15 M NaCl, 0.01% Na₂SO₄, and 2 mM EDTA, pH 7.5) at a rate of 0.3 ml/min in 60 fractions of 500 μl. Lipid composition of fractions corresponding to VLDL, LDL, and HDL were quantified by enzymatic assays using commercially available kits for TC (BioSino, Beijing, China).

Measurement of serum oxidative stress and oxidizability. Serum levels of malondialdehyde (MDA), a marker for oxidative stress, were determined by a spectrophotometric measurement of thiobarbituric acid-reactive substances (TBARS) according to the manufacturer’s instructions (Nanjing Jiancheng Biochemistry, China). The activity of superoxide dismutase (SOD), which acts as antioxidant and protects cellular components from being oxidized by reactive oxygen species, was measured by a commercial kit (Nanjing Jiancheng Biochemistry, China) according to the manufacturer’s instructions. The activity of paraoxonase-1 (PON1), an antioxidant enzyme associated with HDL, was measured by adding serum to 1 ml of Tris-HCl buffer (100 mM, pH 8.0) containing 1 mM CaCl₂ and 1 mM of phenylacetate (Sigma) as described previously (18). The rate of phenyl acetate hydrolysis was determined spectrophotometrically (Uvikon 930 spectrophotometer, Kontron) at 270 nm. PON1 activity was expressed in international units (U) per milliliter of serum. When measuring PON1 activity in lipoproteins, the activity was expressed in international units per gram of protein. The contents of the biologically active oxidized lipids in serum, including 12-hydroxy eicosatetraenoic acid (12-HETE), 13-hydroxy octadecadienoic acid (15-HODE), prostaglandin (PG) and 8-iso-prostaglandin F₂α (8-iso-PGF₂α), were determined by ELISA (Bluegene, Shanghai, China) according to the manufacturer’s instructions.

Measurement of serum inflammatory factors. Serum concentrations of tumor necrosis factor (TNF)-α and interleukin (IL)-6, were determined by ELISA kits (Bluegene, Shanghai, China) according to the manufacturer’s instructions.

Western blots

For serum apolipoprotein measurement, 0.2 μl of serum was denatured at 90°C for 10 min and then subjected to western blot analysis using anti-apoB, anti-apoE, and anti-apoAI antibodies (Abcam). The proteins were visualized and quantified using a chemiluminescence method (Pierce) and Quantity One (Bio-Rad) software program.

Measurement of antioxidant properties of HDL

The serum of every 5–6 patients was pooled, and fasted serum lipoproteins were fractionated by ultracentrifugation at 40,000 rpm in a Beckman Optima LE-80K into VLDL (density less than 1.006 g/ml), LDL (density = 1.006–1.063 g/ml) and HDL3 (density = 1.125–1.21 g/ml) as described previously (19). Fractions were dialyzed in PBS at 4°C and LDL (100 μg protein/ml) was incubated with freshly prepared CuSO₄ (10 μmol/l) in the presence and dyslipidemia (7–9). Metabolic disease remains a serious concern in the world, and people with metabolic syndrome are at increased risk of developing cardiovascular disease, stroke, and type 2 diabetes (9, 10). It is known that the functions and concentrations of serum HDL have strong inverse correlations with risk of metabolic syndrome and atherosclerotic cardiovascular disease (11–13). HDL is known to undergo dramatic modification in structure and composition under the concerted actions of inflammation and oxidative stress (14, 15). As a result, HDL particles progressively lose normal biological activities and acquire altered properties. It is well known that H₂ is an electron donor and therefore has a high reducing ability, and the beneficial effects of H₂ on different disease models are mostly dependent on its antioxidant, anti-inflammatory, and antiapoptotic properties (16). Therefore, it is possible that dyslipidemia-injured HDL function might be improved by H₂ treatment in animals or patients with hyperlipidemia or metabolic syndrome. We have previously demonstrated that administration of H₂-saturated saline markedly improves the functional properties of the HDL particle in mice and golden hamsters (5, 6). However, whether the same effects of H₂ could be observed in humans has not yet been determined. Here, we aimed to characterize the effects of H₂ on functional properties of the HDL particle on 20 patients with potential metabolic syndrome.
were washed three times, and then labeled THP-1 cells (2 × 10⁵ BCECF-AM at 37°C for 1 h in RPMI-1640 medium and were subse-
cacetoxymethyl ester (BCECF-AM), by incubation with 10 µmol/l the methods of Basu et al. (23). RAW264.7 macrophages at 50% Smith et al. (22). Acetyl LDL (AcLDL) was prepared according to human umbilical vein endothelial cells (HUVEC) were grown to confl u-
ence were cholesterol loaded and labeled in 1 ml of RGGB medium was removed for determination of radioactivity. At the end
of the chase period, the macrophages were dissolved in 0.4 ml of 0.1 M sodium hydroxide, and the radioactivity per aliquot was measured. The percentage cholesterol efflux was calculated by divid-
ing the media-derived radioactivity by the sum of the radioactivity in the media and the macrophages.

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
HUVECs were grown to confluence in 96-well plates and pre-
treated with or without HDL (100 µg protein/ml) for 18 h and stimulated with TNF-α (15 ng/ml) for 6 h. Cells treated with me-
dium only served as a negative control group. After removing the supernatant of each well and washing twice with PBS, 10 µl of MTT solution (5 mg/ml in PBS) and 100 µl of medium were then intro-
duced. After incubation for another 4 h, the resultant formazan crystals were dissolved in dimethyl sulfoxide (150 µl), and the absorbance intensity was measured by a microplate reader (Tecan, Sweden) at 490 nm with a reference wavelength of 620 nm. All experiments were performed in quadruplicate, and the relative cell viability was expressed as a percentage relative to the untreated control cells.

LDL oxidation assay
LDL was isolated by ultracentrifugation from the serum. The MDA content of LDL was determined by the measurement of TBARS and expressed as nanomoles per milligram of protein. For determining LDL-mediated inflammation, 100 µg protein/ml of LDL was added to the cultured RAW264.7 macrophages and bone marrow-derived macrophages. After incubation for 24 h, quantitation of the secreted proinflammatory cytokines, including IL-6 and TNF-α, were performed from aliquots of conditioned medium by ELISA (Bluegene, Shanghai, China) according to the manufacturer’s instructions. Bone marrow-derived macrophages in mice were obtained as described previously (24).

Statistical analysis
Statistical analysis was performed by one-way ANOVA (ANOVA) test with the GraphPad Prism v.4.0. Results are expressed as means ± SD. P < 0.05 was considered significant.

RESULTS

Subject characteristics
The baseline demographics of subjects are presented in Table 1. Subjects enrolled in the study included those

| Characteristic | Before Drinking H₂-rich Water | After Drinking H₂-rich Water |
|----------------|-------------------------------|-----------------------------|
| Number of patients | 20                           | 20                          |
| Male            | 12                           | 12                          |
| Female          | 8                            | 8                           |
| Age (years)     | 55.8 ± 10.6                  | 55.8 ± 10.6                 |
| Mean systolic BP (mmHg) | 134 ± 16.6 | 128.8 ± 16.8             |
| Mean diastolic BP (mmHg) | 82.6 ± 11.5 | 80.1 ± 11.5                |
| Height (cm)     | 164.8 ± 8.5                  | 164.8 ± 8.5                 |
| Weight (kg)     | 74.1 ± 13.4                  | 72.0 ± 10.5                 |
| Waist circumference (cm) | 99.7 ± 8.5 | 94.6 ± 6.6               |
| Body mass index (kg/m²) | 27.5 ± 2.6 | 26.5 ± 2.1              |
| Fasting glucose (mmol/l) | 5.7 ± 0.6 | 5.8 ± 1.0               |
| Alcohol use     |                               |                             |
| Daily           | 3                            | 3                           |
| Weekly          | 3                            | 3                           |
| Occasional      | 14                           | 14                          |
| Tobacco use     |                               |                             |
| Yes             | 10                           | 10                          |
| No              | 10                           | 10                          |
TABLE 2. Effect of H₂ on levels of serum lipids and glucose

| Patient | Gender | Smoker? | TC (mM) | LDL-C (mM) | HDL-C (mM) | TG (mM) | Glucose (mM) | TC (mM) | LDL-C (mM) | HDL-C (mM) | TG (mM) | Glucose (mM) |
|---------|--------|---------|---------|-----------|-----------|---------|-------------|---------|-----------|-----------|---------|-------------|
| 1       | M      | N       | 6.96    | 4.2       | 1.34      | 2.24    | 5.93        | 6.15    | 3.14      | 1.2       | 2.26    | 6.33        |
| 2       | F      | N       | 5.91    | 3.88      | 1.35      | 1.71    | 5.67        | 5.77    | 3.73      | 1.37      | 1.04    | 6.52        |
| 3       | F      | N       | 6.4     | 3.88      | 1.82      | 1.07    | 5.72        | 5.83    | 3.29      | 1.6       | 0.94    | 6.36        |
| 4       | F      | N       | 6.23    | 4.01      | 1.15      | 2.01    | 5.52        | 5.32    | 2.94      | 0.85      | 4.05    | 5.39        |
| 5       | F      | N       | 6.92    | 4.44      | 1.5       | 1.68    | 5.18        | 5.42    | 3.46      | 1.39      | 1.72    | 5.18        |
| 6       | F      | N       | 6.47    | 4.47      | 1.42      | 0.87    | 5.52        | 5.6     | 3.78      | 1.33      | 1.6     | 5.69        |
| 7       | F      | N       | 8.26    | 4.69      | 2.01      | 1.66    | 5.54        | 6.62    | 3.8       | 1.71      | 0.93    | 5.59        |
| 8       | M      | N       | 5.12    | 3.29      | 1.11      | 0.83    | 5.02        | 5.17    | 3.38      | 1.23      | 0.71    | 5.06        |
| 9       | F      | N       | 5.66    | 3.7       | 1.34      | 0.64    | 5.12        | 5.29    | 3.28      | 1.35      | 1.24    | 4.57        |
| 10      | M      | N       | 7.21    | 5.1       | 1.48      | 2.21    | 5.01        | 6.54    | 4.12      | 1.5       | 2.23    | 5.06        |
| 11      | F      | Y       | 6.33    | 4.08      | 1.1       | 2.23    | 5.74        | 5.47    | 3.36      | 1.11      | 1.68    | 6.04        |
| 12      | M      | Y       | 6.74    | 4.15      | 1.02      | 3.55    | 5.02        | 5.65    | 3.4       | 1.21      | 1.23    | 5.07        |
| 13      | M      | Y       | 8.22    | 5.21      | 1.56      | 2.56    | 5.98        | 6.36    | 4.19      | 1.42      | 3.09    | 5.47        |
| 14      | M      | Y       | 3.96    | 1.6      | 1.2       | 4.95    | 5.61        | 4.33    | 1.82      | 1.08      | 2.66    | 5.74        |
| 15      | M      | Y       | 7.44    | 3.65      | 1.05      | 4.83    | 4.36        | 5.01    | 2.45      | 1.05      | 5.32    | 4.75        |
| 16      | M      | Y       | 5.91    | 3.51      | 1.14      | 2.77    | 7.2         | 5.82    | 3.41      | 1.12      | 2.22    | 5.8         |
| 17      | M      | Y       | 6.3     | 3.28      | 1.49      | 3.88    | 7.3         | 4.74    | 2.16      | 1.37      | 3.82    | 7.0         |
| 18      | M      | Y       | 7.05    | 4.97      | 1.27      | 1.36    | 5.93        | 5.54    | 3.6       | 1.1       | 1.18    | 6.26        |
| 19      | M      | Y       | 4.09    | 2.55      | 0.72      | 1.62    | 5.23        | 3.36    | 1.82      | 1.26      | 0.67    | 4.95        |
| 20      | M      | Y       | 7.28    | 4.54      | 1.28      | 1.54    | 5.31        | 5.41    | 3.61      | 1.21      | 1.16    | 6.87        |

Mean of nonsmokers: 6.51 ± 0.88, 4.17 ± 0.53, 1.45 ± 0.28, 1.49 ± 0.60, 5.52 ± 0.32, 5.77 ± 0.52, 3.49 ± 0.36, 1.35 ± 0.24, 1.67 ± 1.00, 5.58 ± 0.65

Mean of smokers: 6.33 ± 1.38, 3.75 ± 1.10, 1.18 ± 0.24, 2.95 ± 1.33, 5.77 ± 0.92, 5.17 ± 0.85, 2.98 ± 0.84, 1.19 ± 0.13, 2.30 ± 1.45, 5.79 ± 0.77

Mean of all patients: 6.42 ± 1.13, 3.96 ± 0.86, 1.32 ± 0.29, 2.21 ± 1.24, 5.60 ± 0.69, 5.47 ± 0.75

*P < 0.05 compared with TC levels before drinking H₂-rich water; **P < 0.01 compared with TC levels before drinking H₂-rich water; ***P < 0.05 compared with LDL-C levels before drinking H₂-rich water. M, male; F, female.
significantly (Fig. 3A), and the activity of SOD, which acts as an antioxidant and protects cellular components from being oxidized by reactive oxygen species, was increased after H$_2$ water consumption (Fig. 3B). However, the activity of PON1, an antioxidant enzyme associated with HDL, was not altered in either serum or HDL$_3$ fractions by H$_2$ water (Fig. 3C, D). In addition, we detected serum concentrations of several biologically active oxidized lipids, including 12-HETE, 13-HODE, PG, and 8-iso-PGF$_2$α. The data in Fig. 3E, F shows that 13-HODE and 8-iso-PGF$_2$α levels were improved following the H$_2$ treatment; however, 12-HETE and PG levels were not altered by H$_2$. There was no significant effect of intake of H$_2$ water on serum levels of inflammatory biomarkers, including TNF-α and IL-6 (Fig. 3G, H).

**Effect of H$_2$ on serum lipoprotein profiles and serum levels of antioxidative and inflammatory biomarkers**

The serum lipid levels of each individual are presented in Table 2, and the distribution of lipid levels is shown in Fig. 1. We can see that serum TC and LDL-C levels were significantly decreased after 10 weeks of H$_2$ treatment in all of the 20 patients with potential metabolic syndrome. Among 20 patients, 18 had decreased and 1 (patient 14) had increased TC and LDL-C levels, and 1 (patient 8) was not altered after H$_2$ consumption.

In addition, among the 20 patients, 10 were smokers and 10 were nonsmokers. As shown in Table 2, H$_2$ treatment decreased serum TC and LDL-C levels not only in smokers but also in nonsmokers. And it seems that the lipid-lowering effects of H$_2$ on smokers were better than those on nonsmokers, although there is no significant difference. Serum levels of HDL-C and glucose were not altered by consumption of H$_2$ (Table 2 and Fig. 1C, D). Interestingly, serum TG levels were decreased by H$_2$ treatment in 10 smokers, although there is no significant difference (Table 2), which caused a slight decrease in TG levels in all of the 20 patients (Table 2 and Fig. 1E).

Moreover, serum lipoprotein profile by FPLC further confirmed the decrease in serum LDL-C levels in H$_2$-treated subjects and revealed that serum VLDL-C and HDL-C remained unchanged after intake of H$_2$ water (Fig. 2).

Changes in biomarkers of oxidative and inflammatory status after 10 weeks of consumption of H$_2$ water are shown in Fig. 3. Serum levels of MDA, one of the most frequently used indicators of lipid peroxidation, were decreased significantly (Fig. 3A), and the activity of SOD, which acts as an antioxidant and protects cellular components from being oxidized by reactive oxygen species, was increased after H$_2$ water consumption (Fig. 3B). However, the activity of PON1, an antioxidant enzyme associated with HDL, was not altered in either serum or HDL$_3$ fractions by H$_2$ water (Fig. 3C, D). In addition, we detected serum concentrations of several biologically active oxidized lipids, including 12-HETE, 13-HODE, PG, and 8-iso-PGF$_2$α. The data in Fig. 3E, F shows that 13-HODE and 8-iso-PGF$_2$α levels were improved following the H$_2$ treatment; however, 12-HETE and PG levels were not altered by H$_2$. There was no significant effect of intake of H$_2$ water on serum levels of inflammatory biomarkers, including TNF-α and IL-6 (Fig. 3G, H).

**H$_2$ treatment decreases apoB and apoE protein levels in serum**

Serum LDL and HDL are particles composed of a variety of lipids and protein components; thus, it is necessary to clarify which content of the lipoprotein could be affected

![Fig. 1. Effect of H$_2$ on the levels of serum lipids and glucose. (A) Serum TC, (B) LDL-C, (C) HDL-C, (D) glucose, and (E) TG in patients with potential metabolic syndrome before and after 10 weeks of H$_2$ consumption were determined by enzymatic method. Data (means ± SD, n = 20) were expressed as mmol per liter. H$_2$-B, before drinking H$_2$-rich water; H$_2$-A, after drinking H$_2$-rich water. *P < 0.05, **P < 0.01.](image)

![Fig. 2. FPLC cholesterol profiles using pooled serum samples of n = 5 patients per group showing cholesterol content (mg/dl) of serum lipoprotein fractions.](image)
by H\textsubscript{2} treatment. Consistent with the difference observed for LDL-C, apoB100, the major protein on LDL, was significantly decreased by consumption of H\textsubscript{2} water in patients with potential metabolic syndrome (Fig. 4). The apoE protein, which is mainly present in VLDL and LDL particles, was also lowered with the treatment of H\textsubscript{2} (Fig. 4). ApoAI, the major protein on HDL, was not altered after intake of H\textsubscript{2} water (Fig. 4), which is consistent with the changes observed for HDL-C. These data suggested that H\textsubscript{2} could decrease the expression of the major protein constituents of LDL and VLDL.

**H\textsubscript{2} improves the oxidation and the functional properties of the HDL particle**

HDL is known to undergo dramatic modification in structure and composition under the concerted actions of inflammation and oxidative stress (14, 15). Recent evidence indicates that H\textsubscript{2} acts as a therapeutic medical gas in a variety of disease models by exerting antioxidant and anti-inflammatory effects (3, 25, 26). Therefore, it is possible that administration of H\textsubscript{2} might improve the functional quality of HDL particle. First, H\textsubscript{2} water supplementation tended to decrease the MDA content in HDL3 (Fig. 5A), suggesting that H\textsubscript{2} improves the oxidation of HDL particle.

Second, the biological effect of H\textsubscript{2} on the antioxidative functionality of HDL was tested, namely, the protection of LDL particles from oxidation. As shown in Fig. 5B, H\textsubscript{2} treatment significantly inhibited the formation of TBARS.

Third, the effect of H\textsubscript{2} on the anti-inflammatory properties of HDL was tested, including protection of cytokine-induced monocyte adhesion to endothelial cells and stimulation of endothelial nitric oxide production, which has been suggested as an important endothelial-atheroprotective effect of HDL. As shown in Fig. 5C, after incubation of HUVECs for 6 h with TNF-\alpha, adhesion of monocytes to HUVECs was significantly increased, and preincubation of HUVECs with HDL3 isolated from patients after 10 weeks of drinking H\textsubscript{2} water (HDL-H\textsubscript{2}-A) markedly reduced TNF-\alpha-induced adhesion of monocyte to HUVECs compared with those of HDL3 isolated at baseline (0 week) (HDL-H\textsubscript{2}-B). These data suggest that the anti-inflammatory function of HDL was improved by H\textsubscript{2} water. We also determined the effects of HDL-H\textsubscript{2}-A compared with HDL-H\textsubscript{2}-B on endothelial nitric oxide production. Unfortunately, the nitric oxide production
was not altered significantly after intake of H₂ water (data not shown), which might be attributable to the sensitivity of Griess method.

Fourth, the ability of the isolated HDL particles to elicit efflux from cholesterol-loaded macrophages was tested. As shown in Fig. 5D, HDL particles isolated from the serum after H₂ treatment exhibited dramatically higher efflux properties compared with the HDL particles isolated from the serum before H₂ treatment, indicating that the cholesterol efflux ability mediated by HDL particles was increased by H₂.

Finally, the biological effect of H₂ on the antiapoptotic functionality of HDL was determined. As shown in Fig. 5E, H₂ treatment significantly inhibited TNF-α induced endothelial cell apoptosis. These data indicate that dyslipidemia-injured HDL functions, including the ability to protect against LDL oxidation, the ability to inhibit cytokine-induced monocyte adhesion to endothelial cells, the ability to stimulate cholesterol efflux from macrophage foam cells, and the ability to protect endothelial cell apoptosis, were markedly improved by administration of H₂ water in patients with potential metabolic syndrome.

H₂ reduces the oxidation of LDL and LDL-mediated inflammation

The oxidation of LDL plays an important role in atherogenesis and may influence lipid metabolism. In this study, we determined the effects of H₂ water on the oxidation of LDL and LDL-mediated inflammation. As shown in Fig. 6A, the MDA content of the isolated LDL was reduced by H₂ treatment, suggesting that H₂ reduces the oxidation of LDL. To determine LDL-mediated inflammation, 100 μg protein/ml of the isolated LDL was added to the cultured RAW264.7 macrophages and bone marrow-derived macrophages for 24 h. As shown in Fig. 6B, C, the secretion of TNF-α and IL-6 by macrophages was reduced by H₂ treatment. Furthermore, we tested the effects of H₂ on LDL-induced monocyte adhesion to endothelial cells. As shown in Fig. 6D, consumption of H₂ water significantly decreased LDL-induced monocyte adhesion to endothelial cells. These data reveal that H₂ reduces LDL-mediated inflammatory properties in culture.

**DISCUSSION**

In a previous study, we found that H₂ has beneficial lipid-lowering effects in high-fat diet-fed Syrian golden hamsters (6). However, it remains unknown whether H₂ has effects on lipid and lipoprotein metabolism in humans. The key finding of our present study is that the novel antioxidant chemical element H₂ seems to alleviate lipid metabolism disorder, including hyperlipidemia and defective HDL function, in patients with potential metabolic syndrome. Our results were not consistent with that of human studies in type 2 diabetes mellitus, as they showed significant decreases in modified LDL-C levels and no effect on total and LDL-C (3). The inconsistency might be attributable to the difference in pathological conditions, the dosage of administration, or the intervention period. Despite this possibility, the discrepancy might be explained by the fact that modified LDL, like oxidized LDL, largely existed in the hyperlipidemia model, which was used in our study.

Subanalysis was conducted on 20 subjects, and we found the serum TC levels of 17 subjects with hyperlipidemia (TC > 5.18 mmol/l) was decreased by intake of H₂ water for 10 weeks, and the serum TC levels of the remaining 3 subjects without hyperlipidemia (TC < 5.18 mmol/l) was not significantly altered by H₂ treatment, although the TC level of 1 subject was slightly increased after treatment (Table 2, patient 14). The data gave us a clue that H₂ might exert a lipid-lowering effect on the patients with hyperlipidemia but have little effect on the population without hyperlipidemia.

It is well known that high cholesterol level is one of the important risk factors for atherosclerosis. Therefore, the elucidation of the mechanism by which H₂ decreases serum cholesterol will provide solid evidence for the application of H₂ in cardiovascular disease therapy. Serum LDL and VLDL are particles composed of a variety of lipids and protein components; thus, it is necessary to clarify which content of the lipoprotein could be affected by H₂ treatment. First, LDL is a contributing factor to the development of atherosclerosis. ApoB100 is the major protein present in LDL particles, and like LDL-C, the serum apoB level has been positively correlated with risk for atherosclerotic disease. In the present study, we found H₂ treatment not only decreased serum LDL-C levels, but also remarkably lowered apoB100 and apoE protein levels in serum. The data gave us a clue that H₂ might regulate the metabolism of LDL-C by decreasing the synthesis of apoB or increasing the catabolism of LDL-C. Second, like LDL-C, VLDL-C is considered a type of “bad” cholesterol because elevated levels are associated with an increased risk of coronary artery disease (27). We found that apoB and apoE, the major proteins in VLDL, were lowered by H₂, although cholesterol analysis by FPLC revealed no changes of
Fig. 5. \( \text{H}_2 \) seems to improve the oxidation and functional properties of the HDL particle. Serum of every 5–6 patients was pooled, and HDL3 was isolated by ultracentrifugation from the serum. (A) MDA content in HDL3 particles. HDL function was determined as (B) protection of LDL against oxidation, (C) inhibition of TNF-\( \alpha \)-induced THP-1 monocyte adhesion to endothelial cells, (D) stimulation of cholesterol efflux from macrophage foam cells, and (E) protection of endothelial cells from TNF-\( \alpha \)-induced apoptosis. Assays were performed as detailed in Methods. \( n = 3–4 \) pooled serum samples. *\( P < 0.05 \), **\( P < 0.01 \).

VLDL-C after \( \text{H}_2 \) treatment. The inconsistencies in protein and cholesterol levels might be explained by the suspicion that the functional target of \( \text{H}_2 \) might be apolipoprotein expression, not cholesterol. Taken together, the data indicate that molecular \( \text{H}_2 \) dissolved in water might have a beneficial regulating effect on lipid abnormality in patients with metabolic syndrome, especially in patients with hyperlipidemia. This effect is partially related to its regulation of lipid and protein contents of LDL and VLDL. Further experiments are needed to identify the mechanisms by which \( \text{H}_2 \) regulates the lipid and protein contents of lipoprotein particles and improves the serum lipoprotein profile. Previous studies have demonstrated that administration of \( \text{H}_2 \)-rich saline improves insulin sensitivity (3), which, in our view, could partly contribute to the improved lipid metabolism in our study. Furthermore, liver cells sense the reduced levels of hepatic intracellular cholesterol and seek to compensate by synthesizing LDL receptors to draw cholesterol out of the circulation (28). Future studies on hepatic HMG-CoA reductase and LDL receptors may elucidate the mechanism by which \( \text{H}_2 \) acts on lipoprotein regulation.


Fig. 6. \( \text{H}_2 \) seems to reduce oxidation of LDL in patients and LDL-mediated inflammation in macrophages. Serum of every 5–6 patients was pooled, and LDL was isolated by ultracentrifugation from the serum. (A) MDA content of the isolated LDL. (B) One hundred micrograms of protein per milliliter of isolated LDL was added to cultured RAW264.7 macrophages. Supernatants were harvested at 24 h for measurement of TNF-\( \alpha \) and IL-6 by ELISA assay. (C) One hundred micrograms of protein per milliliter of isolated LDL was added to the cultured bone marrow-derived macrophages, and cytokines in medium were measured after 24 h incubation. (D) HUVECs were stimulated with LDL (100 \( \mu \)g protein/ml) for 6 h and THP-1 cells, labeled with a fluorescent dye BCECF-AM, were added to HUVECs. After adhering, THP-1 cells bound to HUVECs were counted under fluorescent microscope as described in Methods. Results are expressed as means ± SD (n = 3–4 pooled serum samples). \(* P < 0.05.\)

HDL is known to protect against the development of atherosclerosis and is widely documented as a “negative risk factor” for coronary heart diseases (29). The antiatherogenic activity of HDL is principally attributable to a variety of antioxidative, anti-inflammatory, and antiapoptotic properties and the reverse transport of cholesterol (30). In the present study, we found \( \text{H}_2 \) treatment seems to improve the functionality of HDL3 without altering HDL-C serum levels. It is known that the beneficial effects of \( \text{H}_2 \) on different disease models are mostly dependent on its antioxidative, anti-inflammatory, and antiapoptotic properties (16). Therefore, it is possible that the protective effect of \( \text{H}_2 \) on HDL function in our study is attributable, at least in part, to the antioxidative and anti-inflammatory properties of \( \text{H}_2 \). A number of therapeutic strategies are being developed to target HDL-C in an attempt to inhibit the progression or induce regression of atherosclerosis and reduce cardiovascular events. Therefore, the protective effect of \( \text{H}_2 \) on HDL function in the our study might provide a further evidence for \( \text{H}_2 \) application in vascular disease therapy. We did not observe any unwanted side effects of \( \text{H}_2 \), including headache, diarrhea, and vomiting (data not shown), suggesting fewer toxic and adverse effects of \( \text{H}_2 \).

The oxidation of LDL plays an important role in atherogenesis and may influence lipid metabolism. Our data reveals that \( \text{H}_2 \) seems to reduce the oxidation of LDL and LDL-mediated inflammation, and they further support our prediction that \( \text{H}_2 \) might improve lipid metabolism in patients with hyperlipidemia by inhibiting LDL-mediated inflammation. Previous studies have demonstrated that administration of \( \text{H}_2 \) reduces atherogenesis in apoE\(^{-/-}\)mice (5); in our view, this could partly contribute to the observed protective effects of \( \text{H}_2 \) on the oxidation of LDL and LDL-mediated inflammation in our study.

Indeed, our data give us a clue that \( \text{H}_2 \) might have the potential to be used as a novel lipid-regulating agent with the advantage of no toxicity compared with other commonly used lipid-regulating drugs that have side-effects on the liver and kidney. Further understanding of the mechanisms underlying the signaling pathways involved in the ability of \( \text{H}_2 \) to influence lipid and cellular metabolism is required to fully exploit intake of \( \text{H}_2 \) gas as a therapeutic strategy.

There are several limitations to the present study. First, the number of subjects recruited is small and it is hard to draw a solid conclusion, particularly having smokers among the subjects. It should, however, be emphasized that we analyzed the data in smokers and nonsmokers separately, and the response to \( \text{H}_2 \) in smokers seems to be stronger than that in nonsmokers, but the difference did
not reach statistical significance. It would be useful to enlarge the sample size and examine the reaction to H₂ in smokers due to the antioxidative property of H₂. Another limitation of the study was that it was not a double-blind, randomized, controlled trial comparing H₂-rich water to placebo and comparing experimental endpoints from H₂-treated metabolic syndrome subjects with those measured in untreated healthy individuals. It is possible that during the 10 weeks of the study, the subjects altered their lifestyles, which could have affected the parameters studied. Therefore, it is difficult for us to draw a solid conclusion, and it limits the conclusions to stating that H₂ treatment may regulate lipid metabolism in patients.

In summary, our data show that in vivo administration of H₂ water seems to decrease serum TC and LDL-C levels and improve HDL functions in patients with potential metabolic syndrome, suggesting that H₂ may be used as a new pharmacological agent to treat or control lipid metabolism disorder.

REFERENCES

1. Ohsawa, I., M. Ishikawa, K. Takahashi, M. Watanabe, K. Nishimaki, K. Yamagata, K. Katsura, Y. Katayama, S. Asoh, and S. Ohta. 2007. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 13: 688–694.
2. Amatuni, H., A. Asakawa, K. Cheng, M. Amatuni, K. Kaimoto, M. Nakano, M. Ushiki, Y. Li, M. Tsai, J. B. Li, et al. 2013. Hydrogen improves glycemic control in type 1 diabetic animal by promoting glucose uptake into skeletal muscle. PLoS ONE 8: e59513.
3. Kajiyama, S., G. Hasegawa, M. Asano, H. Hosoda, M. Fukui, N. Nakamura, J. Kitawaki, S. Imai, K. Nakano, M. Ohta, et al. 2008. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr. Res. 28: 137–143.
4. Gharib, B., S. Hanna, O. M. Abdallah, H. Lepidi, B. Gardette, and M. De Reggi. 2001. Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. C. R. Acad. Sci. III 324: 719–724.
5. Song, G., H. Tian, S. Qin, X. Sun, S. Yao, C. Zong, Y. Luo, J. Liu, Y. Yu, H. Sang, et al. 2012. Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice. Atherosclerosis. 221: 55–65.
6. Zong, C., G. Song, S. Yao, L. Li, Y. Yu, L. Feng, S. Guo, T. Luo, and S. Qin. 2012. Administration of hydrogen-saturated saline decreases plasma low-density lipoprotein cholesterol levels and improves high-density lipoprotein function in high-fat diet-fed hamsters. Metabolism. 61: 794–800.
7. Furukawa, S., T. Fujita, M. Shimabukuro, M. Iwaki, Y. Yamada, Y. Nakajima, O. Nakayama, M. Makishima, M. Matsuda, and I. Shimomura. 2004. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 114: 1752–1761.
8. Holvoet, P., D. H. Lee, M. Steffes, M. Gross, and D. R. Jacobs, Jr. 2008. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 299: 2287–2293.
9. Ford, E. S., W. H. Giles, and W. H. Dietz. 2002. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 287: 356–359.
10. Grundy, S. M., H. B. Brewer, Jr., J. I. Cleeman, S. C. Smith, Jr., and C. Lenfant. 2004. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 109: 435–438.
11. Cifuentes-Goches, J. C., D. Gomez-Lopez Jde, L. Hernandez-Aneyeta, S. E. Flores-Fuentes, J. L. Inchaustegui-Arias, and A. O. Canas-Urbina. 2012. Hypertriglyceridemia and low HDL cholesterol as high impact factors for metabolic syndrome diagnosis in apparently healthy adults [in Spanish]. Rev. Med. Inst. Mex. Seguro Soc. 50: 301–306.
12. Van Lenten, B. J., M. Navab, D. Shih, A. M. Fogelman, and A. J. Lusis. 2001. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 11: 155–161.
13. Tamada, M., S. Makita, A. Abiko, Y. Naganuma, M. Nagai, and M. Nakamura. 2010. Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis. Metabolism. 59: 653–657.
14. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism; mechanisms and consequences to the host. J. Lipid Res. 45: 1169–1196.
15. Esteve, E., W. Ricart, and J. M. Fernandez-Real. 2005. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. 24: 16–31.
16. Suzuki, Y., M. Sano, K. Hayashida, I. Ohsawa, S. Ohta, and K. Fukuda. 2009. Are the effects of alpha-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract? FEBS Lett. 583: 2157–2159.
17. Jiang, X. C., L. Masucci-Magoulas, J. Mar, M. Lin, A. Walsh, J. L. Breslow, and A. Tall. 1993. Down-regulation of mRNA for the low density lipoprotein receptor in transgenic mice containing the gene for human cholesterol ester transfer protein. Mechanism to explain accumulation of lipoprotein B particles. J. Biol. Chem. 268: 27406–27412.
18. Itahara, T., T. Suehiro, Y. Ikeda, M. Inoue, T. Nakamura, Y. Kuman, M. Kawada, and K. Hashimoto. 2000. Serum paraoxonase and arylesterase activities in hemodialysis patients. J. Atheroscler. Thomb. 7: 152–153.
19. Jiang, X. C., C. Bruce, J. Mar, M. Lin, Y. Ji, O. L. Francone, and A. R. Tall. 1999. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103: 907–914.
20. Rikitake, Y., K. Hirata, S. Kawashima, H. Akita, and M. Yokoyama. 1998. Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells. Atherosclerosis. 136: 51–57.
21. McCrohon, J. A., W. Jessup, D. J. Handelsman, and D. S. Celemajer. 1999. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. 99: 2517–2522.
22. Smith, J. D., M. Miyata, M. Ginsberg, C. Gräux, E. Shmookler, and A. S. Plump. 1996. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J. Biol. Chem. 271: 30647–30655.
23. Basu, S. K., M. S. Brown, Y. K. Ho, R. J. Havel, and J. L. Goldenstein. 1981. Mouse macrophages synthesize and secrete a protein resembling apolipoprotein. Proc. Natl. Acad. Sci. USA. 78: 7545–7549.
24. Niall, M., Y. Sadahira, S. Kawasaki, T. Hayashi, and M. Awai. 1990. Macrophage heterogeneity in bone marrow culture in vitro. J. Cell Sci. 95: 481–485.
25. Ohsawa, I., K. Nishimaki, K. Yamagata, M. Ishikawa, and S. Ohta. 2008. Consumption of hydrogen water prevents atherosclerosis in apolipoprotein E knockout mice. Biochem. Biophys. Res. Commun. 377: 1195–1198.
26. Kolowou, G., K. Anagnostopoulou, D. P. Mikhalidis, and D. V. Kokkinos. 2008. Apolipoprotein E knockout models. Curr. Pharm. Des. 14: 338–351.
27. Geurian, K. J., B. Pinson, and C. W. Weart. 1992. The triglyceride connection in atherosclerosis. Ann. Pharmacother. 26: 1109–1117.
28. Ma, P. T., G. Gill, T. C. Sudhof, D. W. Bilheimer, J. L. Goldenstein, and M. S. Brown. 1986. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl. Acad. Sci. USA. 83: 8370–8374.
29. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62: 707–714.
30. Kontush, A., and M. J. Chapman. 2006. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58: 342–374.